Efficacy and safety of Ferric carboxymaltose injection compared with oral iron for the treatment of postpartum anemia in Japan: a randomized controlled clinical trial

Efficacy and safety of Ferric carboxymaltose injection compared with oral iron for the treatment of postpartum anemia in Japan: a randomized controlled clinical trial - Efficacy and safety of Ferric carboxymaltose injection compared with oral iron for the treatment of postpartum anemia in Japan: a randomized controlled clinical trial

Status

Active, not recruiting

Phases

Unknown

Study type

Interventional

Source

JPRN

Registry ID

JPRN-UMIN000046049

Enrollment

Registered

2021-12-01

Start date

2021-12-01

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

postpartum anemia

Interventions

Ferric carboxymaltose injection 500mg twice every two weeks. Dried Ferrous Sulfate 210mg per day for 4 weeks

Eligibility

Sex/Gender

Female

Inclusion criteria

Inclusion criteria: Patients with Hb less than 10g/dL and ferritin less than 500 ng/mL after vaginal delivery or cesarean section. Patients weighing 35 kg or more

Exclusion criteria

Exclusion criteria: 1) Patients whose CRP level measured exceeds 20 mg/L (2) Patients with hematological diseases (3) Patients with serious hepatic disorder, renal disorder, or cardiovascular disease 4) Persons who have received a blood transfusion within 1 week (5) Patients with malignant tumors (6) Patients with a history of serious drug allergy such as anaphylactic shock or a history of serious adverse drug reactions.

Design outcomes

Primary

Measure	Time frame
Change in Hb level after 2 weeks of treatment	—

Countries

Japan

Contacts

Public ContactTakeshi Nagao

Jikei university school of medicine Division of obstetrics and gynecology

takeshi.n.900113@gmail.com03-3433-1111

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026